News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals Inc. (INFI) Reports First Quarter 2014 Financial Results and Provides Company Update


5/7/2014 8:03:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2014 financial results and ongoing progress with IPI-145, the company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

“Infinity continues to execute on DUETTS, a worldwide development program of IPI-145, in hematologic malignancies,” commented Adelene Q. Perkins, chief executive officer of Infinity Pharmaceuticals. “We are pleased by the ongoing investigator and patient enthusiasm for DYNAMO, our Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, and expect to initiate DYNAMO+R, our Phase 3 combination study in patients with indolent non-Hodgkin lymphoma, in the second half of this year. We are also excited to have initiated in the first quarter patient enrollment in DUO, our Phase 3 study of IPI-145 in patients with chronic lymphocytic leukemia.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES